BioCentury
ARTICLE | Company News

Novartis suit, gliptin review to continue in Germany

March 1, 2013 2:49 AM UTC

A German court on Thursday said pending litigation from Novartis AG (NYSE:NVS; SIX:NOVN) is not cause for suspending the review of marketed dipeptidyl peptidase-4 (DPP-4) inhibitors by Germany's Federal Joint Committee (G-BA). The written decision from the State Social Court for the States of Berlin and Brandenburg also clarified that AMNOG law does not explicitly prohibit litigation over benefit assessments of drugs launched before AMNOG came into effect. Court spokesperson Axel Hutschenreuther said a decision on the case is expected in May or June (see BioCentury, Feb. 18). ...